Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
Takeda Pharmaceutical will revamp its organizational structure effective April 1 as the company prepares for the leadership transition — the first in 12 years — to CEO-elect Julie Kim in June 2026. The biggest change is the creation of a…
To read the full story
Related Article
- Takeda Turns the Page to Kim’s “10-Year” Era, Betting on New Drugs and AI
June 26, 2026
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 24, 2026
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- Takeda Unveils Annual 200 Billion Yen Cost Savings by FY2028
March 26, 2026
- Takeda Zeros in on US Successor Ahead of 2026 CEO Transition
June 26, 2025
- Julie Kim Tapped to Take Over Helm of Takeda in 2026
January 31, 2025
BUSINESS
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
- Takeda Files Entyvio IV for Pediatric Use, New Adult Dosing in Japan
July 29, 2026
- Otsuka Ups 1H Guidance on Strong Sales, Delayed Generic Competition
July 29, 2026
- Japan OTC Market Falls for 4th Straight Month in June: Intage
July 29, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…